EC109 Orthotopic Mouse Model Service for Esophageal Cancer

The EC109 orthotopic mouse model for esophageal cancer recreates human esophageal squamous cell carcinoma within its native anatomical site, delivering a biologically faithful setting in which tumor behavior and therapy response can be evaluated preclinically. Alfa Cytology offers comprehensive development of this model, covering authenticated cell expansion, minimally invasive surgical implantation, longitudinal tumor monitoring, and full histopathological endpoint analysis, giving your oncology program a translationally relevant platform built on rigorous quality standards.

Overview of EC109 Orthotopic Mouse Model for Esophageal Cancer

The EC109 cell line is a well-characterized human esophageal squamous cell carcinoma (ESCC) line originally derived from a middle-esophageal tumor of a female patient of Chinese ethnicity. When established as an orthotopic xenograft, EC109 cells are implanted directly into the esophageal wall of immunodeficient mice rather than into the subcutaneous flank, allowing the tumor to develop in the anatomical and physiological context of the native esophagus. This setting preserves critical tumor–stroma interactions, local vascular supply, and organ-specific mechanical cues, so the resulting lesions more closely mirror the growth pattern, histology, and microenvironmental dependence of human esophageal tumors.

Fig 1. Bioluminescence monitoring of luciferase-expressing ECA109 esophageal squamous carcinoma cells in vivo, demonstrating reporter-based quantitative assessment of tumor burden and therapeutic response. (Peng, Shang, et al., 2025)

Compared with conventional subcutaneous xenografts, the orthotopic EC109 model more faithfully reproduces features that matter in preclinical decision-making: nutrient-limited growth kinetics, invasion into adjacent esophageal layers, and clinically relevant routes of regional progression. These characteristics make the model particularly valuable for testing chemotherapeutics, targeted agents, combination regimens, and experimental delivery strategies under conditions that better approximate the human disease. Orthotopic modeling also supports longitudinal assessment through non-invasive imaging, enabling tumor burden to be tracked over time without sacrificing cohorts at each time point.

Cell Line Information: EC109

EC109 (also cataloged as Eca-109, EC-109, or Eca109) is a continuously propagated human ESCC line that has been widely adopted in esophageal cancer research for decades. Because certain distributed stocks have been reported to carry HeLa contamination, the line is flagged by the International Cell Line Authentication Committee (ICLAC); accordingly, only lot-specific, STR-authenticated and mycoplasma-tested material should be used for model construction. Key documented attributes are summarized below.

Our Services

Alfa Cytology brings together surgical oncology expertise, authenticated cell line resources, and disciplined in vivo study management to deliver the EC109 orthotopic esophageal cancer model as a dependable preclinical tool. From feasibility assessment and pilot tumorigenicity runs to fully powered efficacy studies with imaging and histology readouts, every engagement is executed under a clearly defined protocol and quality framework—so you receive decision-ready data rather than raw readouts.

Workflow of EC109 Orthotopic Mouse Model Construction

Construction of the EC109 orthotopic model follows a standardized, quality-controlled sequence in which each phase feeds a defined checkpoint before the next begins. The typical workflow comprises the following steps:

1. Cell line authentication and expansion: EC109 cells from a verified, low-passage stock are STR-profiled and tested for mycoplasma, then expanded under standardized conditions to generate a qualified inoculum.
2. Pre-implantation cell preparation: Cultures are harvested at optimal confluence, counted and viability-checked, then formulated—often mixed with a basement membrane matrix—at a defined concentration (commonly on the order of 2 × 10⁶ cells per inoculum).
3. Animal preparation and anesthesia: Immunodeficient mice are acclimatized, randomized, and anesthetized; analgesia and aseptic technique are applied in line with institutional animal welfare requirements.
4. Surgical exposure of the esophagus: A small cervical or abdominal incision provides controlled access to the esophageal segment selected for implantation, minimizing tissue trauma and operative time.
5. Orthotopic implantation: The EC109 cell suspension is carefully introduced into the esophageal wall (or applied onto the exposed serosal surface), and the site is closed with fine sutures so the inoculum remains confined to the organ.
6. Postoperative recovery: Animals are monitored until fully recovered, with body weight, feeding behavior, and surgical wound condition recorded daily during the early postoperative period.
7. Longitudinal tumor monitoring: Tumor establishment and growth are tracked non-invasively where reporter-labeled cells are used, supplemented by clinical observation, so that randomization into treatment arms occurs at a consistent tumor burden.
8. Endpoint analysis: At study termination, tumors are excised, measured, and processed for histopathology, immunohistochemistry, and molecular analyses, with full documentation delivered to the client.

Fig 2. EC109 orthotopic mouse model construction workflow.

Case Study-EC109 Orthotopic Mouse Model Development

Alfa Cytology has supported preclinical programs in which the EC109 orthotopic esophageal cancer model was developed and applied to evaluate candidate therapeutics under organ-relevant conditions. These engagements typically span model feasibility assessment, establishment of reproducible tumor growth parameters, and the execution of treatment studies with longitudinal monitoring and histopathological endpoints. Representative case summaries and study data can be shared upon request as your program moves from exploratory discussions into study design.

Why Choose Alfa Cytology?

Selecting a CRO for orthotopic modeling is ultimately about trusting the quality of the biology, the surgery, and the data. Alfa Cytology is structured to deliver on all three for the EC109 esophageal cancer model:

• Specialized surgical team with hands-on experience in orthotopic esophageal implantation, supporting high take rates and consistent tumor growth.
• Strict cell line quality control, including STR authentication and mycoplasma screening before every study start.
• Customizable study designs spanning feasibility, pharmacokinetic–pharmacodynamic, and efficacy endpoints tailored to your candidate mechanism.
• Longitudinal monitoring capabilities, including bioluminescence imaging and scheduled clinical assessments, to preserve statistical power.
• Comprehensive endpoint packages combining gross pathology, histology, immunohistochemistry, and molecular readouts in a single delivery.
• A preclinical-only focus that keeps the entire workflow aligned with early-stage research goals, timelines, and budgets.

Contact Us

If the EC109 orthotopic mouse model for esophageal cancer fits your preclinical research plans, we would be glad to discuss feasibility, timelines, and study design. Reach out to us with your project requirements, and the Alfa Cytology team will respond with a tailored proposal and technical guidance to move your program forward.

For research use only. Not intended for any clinical use.